article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

Pharmaceutical companies and biotechs are also adapting their approaches, launching patient finding and engagement programmes that can start years before clinical trials begin and allow them to run ‘recontact by genotype’ studies that the Resilience Project would have liked to do. Giving participants something in return.

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

A 2015 study published in Nature Genetics found that the availability of human genetic data made investigational drugs twice as likely to pass pivotal trials and eventually be approved. Using Deep Clinical Data and WGS to Better Subtype Heart Failure Patients. Genuity Science Drug Target Discovery Study.